Preventing prostate cancer cells from 'bodybuilding' provides new treatment hope
Cancer Research UK scientists have discovered that stopping prostate cancer cells from ‘bulking up’ with nutrients reduces the spread of the disease and tumour size, according to research published today in EMBO Journal.
Prostate cancer is partly driven by cell signals from the androgen receptor (AR) protein AR. One gene regulated by AR’s signals is the well-known prostate cancer biomarker, Prostate Specific Antigen (PSA). But the full network of genes controlled in this way is not yet known.
Scientists from Cancer Research UK’s Cambridge Research Institute at the University of Cambridge searched through the DNA in prostate cancer cells to identify genes controlled by AR and find new potential ways to detect and treat the disease.
The team identified a number of AR-controlled genes, including the gene that codes for the enzyme CAMKK2*** which controls glucose consumption in cells.
The other genes were also mainly linked to metabolism – the generation of energy, and controlled cancer cells’ ability to absorb glucose. High levels of glucose are required by cancer cells for growth and division and to power important ‘construction’ work to produce cellular building blocks - fats, proteins, DNA and RNA.
They discovered that there were unusually high levels of CAMKK2 in prostate cancer cells.
The team then showed in mice that stopping both the production and activity of CAMKK2, blocked the spread of prostate cancer cells and reduced the tumour size. Measuring levels of the enzyme could also be used as a ‘biomarker’ or test to detect prostate cancer.
Lead author, Dr Ian Mills, said: “We’ve discovered a network of genes which control how prostate cancer cells ‘bulk up’ before they divide. And importantly we’ve shown that blocking one of these genes will starve the cancer cells of vital nutrients – and reduce tumour size and spread of the disease.
“More research to understand how prostate cancer cells generate energy could open up new routes to detect and treat the disease.”
Prostate cancer is the most common cancer in men in the UK with around 37,000 cases diagnosed each year.
Dr Lesley Walker, Cancer Research UK’s director of cancer information, said: “Cancer Research UK is a major funder of research into prostate cancer in the UK - transforming our understanding of the disease and how best to detect and treat it.
“And this important study shows that investigating the way prostate cancer cells use and generate energy could provide a promising new route to search for ways to detect and treat different stages of the disease, to continue to improve survival from prostate cancer in the future.”
For media enquiries please contact the press office on 020 3469 8300 or, out-of-hours, the duty press officer on 07050 264 059.
The androgen receptor fuels prostate cancer by regulating central metabolism and biosynthesis. Massie et al. EMBO Journal.
Notes to Editor
The PSA test helps doctors work out how likely a man is to have prostate cancer. But there is currently no national screening programme for prostate cancer.
This is because the PSA test isn’t as reliable enough to be a screening test. And there is not enough evidence that the benefits of PSA testing outweigh the harms.
PSA or prostate-specific antigen, is a chemical produced by the prostate. PSA levels can be measured in the blood and are often raised when a man has prostate cancer. But they can also be raised when a man has a less serious condition called benign prostatic hyperplasia, which causes the prostate gland to enlarge.
Testing for PSA is complicated by the fact that all men have slightly different levels of PSA, so it is hard to say what level is ‘normal’, and what is ‘high’. This means that not all men with high PSA levels have prostate cancer. And not all men with prostate cancer have high PSA levels.
***CAMKK2 - Calcium/calmodulin-dependent protein kinase kinase 2.